Business Context and Reporting Period
This Form 8-K, dated December 31, 2020, reports the completion of a Share Exchange Agreement by Bionexus Gene Lab Corp. (the "Company") to acquire 100% of the outstanding shares of Chemrex Corporation Sdn. Bhd. ("Chemrex"), a Malaysian industrial chemical supply chain company. The transaction closed on December 31, 2020.
Key Financial Metrics
Chemrex Financial Performance (Target Company):
- Fiscal Year 2019 (Audited): Revenue of $15,636,064; Net Profit of $308,083.
- Fiscal Year 2020 (Unaudited): Revenue of $18,180,502; Net Income of $848,014.
- Revenue Composition: Approximately 75% derived from resin sales.
Transaction Consideration and Capital Structure:
- Shares Issued: 68,487,261 shares of Bionexus common stock issued to Chemrex shareholders.
- Pre-Transaction Outstanding Shares: 102,730,891.
- Post-Transaction Outstanding Shares: 171,218,152.
Liquidity and Debt: The filing text does not provide specific values for Bionexus's cash flow, debt levels, or liquidity ratios. The transaction was funded entirely through equity issuance.
Material Changes Versus Prior Period
- Acquisition: The Company expanded its operations by acquiring Chemrex, which serves industrial and medical component manufacturers in South East Asia, the Middle East, and India.
- Ownership Structure: The issuance of nearly 68.5 million shares significantly diluted pre-existing shareholders, increasing total outstanding shares by approximately 66.6%.
- Management Changes: Liong Tai Tan, a former Chemrex shareholder, received 14,553,543 shares and serves as Chief Operating Officer (appointed November 27, 2020).
Guidance, Outlook, and Risks
Forward-Looking Statements: The filing includes standard cautionary notes regarding the uncertainty of future results, specifically highlighting risks related to the Company's ability to raise sufficient capital to finance planned operations.
Regulatory Compliance: The sale of shares to Chemrex shareholders was effected under Regulation S, as the shareholders are non-US persons.
Missing Financial Data: Pro forma financial information and audited financial statements for the acquired business are not included in this filing. They are scheduled to be filed by amendment within 71 calendar days.
Investor Verification Checklist
- Verify the upcoming filing of pro forma financial statements and audited Chemrex financials within the 71-day window.
- Confirm the valuation implied by the 68,487,261 shares issued relative to Chemrex's 2020 net income of $848,014.
- Review the beneficial ownership table to assess the concentration of control among the new Chemrex shareholders and existing directors.
- Monitor the Company's capital raising efforts as explicitly flagged in the forward-looking risk statements.